MK-2206 2HCl

製品コードS1078

MK-2206 2HCl化学構造

分子量(MW):480.39

MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。

サイズ 価格 在庫  
USD 277 あり
USD 138 あり
USD 214 あり
USD 466 あり
USD 718 あり

文献中の引用(180)

カスタマーフィードバック(19)

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

製品安全説明書

Akt阻害剤の選択性比較

生物活性

製品説明 MK-2206 2HCl は一種の高選択性のAkt1/2/3阻害剤で、無細胞試験でIC50値が8 nM/12 nM/65 nMそれぞれに分かれて、250種類他のタンパク質キナーゼに抑制活性を表しません。臨床2期。
特性 The first allosteric small molecule inhibitor of Akt to enter clinical development.
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro試験

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MoTnR5l1d3SxeHnjJGF{e2G7 MoL6N{DPxE1? NVn0WoNDPzJiaB?= NH7UO4NFVVOR MUTJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NXS4OnVFOjB3N{GwOlk>
A431 NGPPboVMcW6jc3WgRZN{[Xl? MWm1JO69VQ>? M1rLZVUhcA>? MVPEUXNQ M3nXWnN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? M{P1bFIxPTdzME[5
HepG2 NHXIXm5EgXSxdH;4bYMhSXO|YYm= Mm\mNVAh|ryP M2j1XFI1KGh? Mo\jSG1UVw>? M1P5V3NmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> M2TlT|IyOjB3OUK1
Sk-Hep1 MmX3R5l1d3SxeHnjJGF{e2G7 M4\qeVExKM7:TR?= NVzwUXFEOjRiaB?= MVvEUXNQ M3HiSHNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> NGThbJUzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\QO|Mh|ryP MXG1JIQ> NGTtVpdFVVOR NFTaNIVKSzVyPUCuNVQh|ryP NUHhOY8{OjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mzfFMh|ryP NEHNUmc2KGR? M3Swd2ROW09? MXTJR|UxRTBwNUKg{txO MYCyNVI5QTJ4Nx?=
FTC133 cells harbored PTEN (allele deletion and R130+) Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHzfIk4OyEQvF2= NWDPfJZ3PSCm M13EWmROW09? NGC1bGVKSzVyPUCuNVgh|ryP MmPKNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) NX7SO|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\BT|Mh|ryP NITRVmc2KGR? MorySG1UVw>? NGrk[YNKSzVyPUCuNlch|ryP MXmyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−) NWLBUFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOzJO69VQ>? NHHubII2KGR? MV;EUXNQ NUTCenh3UUN3ME20MlUh|ryP MWOyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement NGnFOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHhN{DPxE1? M3PVWFUh\A>? M4jvUWROW09? MmDETWM2OD1yLkW5JO69VQ>? M3n6XlIyOjh7Mk[3
Hth74 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnpe2Q{KM7:TR?= NEjESGM2KGR? MX7EUXNQ NYnmcZp7UUN3ME2yMlE6KM7:TR?= NUD1Zo57OjF{OEmyOlc>
KAT18 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXDcoFvOyEQvF2= M3i1d|Uh\A>? MUjEUXNQ MUHJR|UxRTRwNkKg{txO MkPoNlEzQDl{Nke=
SW1736 NXfBNXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNFAh|ryP M4n2TFUh\A>? M3;vW2ROW09? M3j4PWlEPTB;NEeuOVYh|ryP NWDLVWxTOjF{OEmyOlc>
WRO Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy2Om16OTByMDFOwG0> NF;3[m02KGR? M{\ES2ROW09? NH\JfpJKSzVyPkGwNFAh|ryP Mn7ZNlEzQDl{Nke=
TAD2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS0NVAxOCEQvF2= MlGxOUBl NWfaZ21mTE2VTx?= M{X4fGlEPTB-MUCwNEDPxE1? NGHjPXIzOTJ6OUK2Oy=>
LN229 Ml\XRZBweHSxc3nzJGF{e2G7 MkDGNE42KM7:TR?= MXm2NEBp Ml71SG1UVw>? M4TxUWF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk MWKyNlA2PzlzNB?=
T98G NE\VT5ZCeG:ydH;zbZMhSXO|YYm= MXuwMlUh|ryP M3fGblYxKGh? MknPSG1UVw>? M1uxZmF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk NWHWfXFtOjJyNUe5NVQ>
HC11 M4DWfmZ2dmO2aX;uJGF{e2G7 NUH5dWZbOTBizszN MVOyOEBp M37U[mROW09? NGfIPWFKdmirYnn0d{DPui2lYYPlbY4h[W6mIFHEVnAhe3mwdHjld4l{ MkHLNlI1OjZ4MkG=
MOLT-4 MX;DfZRwfG:6aXOgRZN{[Xl? NUHsN45oOTBizszN MXm0PEBp MXLEUXNQ Mm\aTWM2OD1zLkhihKnPxE1? MY[yNlYyPDJ2Mx?=
CEM-R NGTje4REgXSxdH;4bYMhSXO|YYm= NEDZeGIyOCEQvF2= MUC0PEBp M1i2cWROW09? M4S3N2lEPTB;Mz6z5qCK|ryP NH[4fXEzOjZzNEK0Ny=>
CEM-S MWfDfZRwfG:6aXOgRZN{[Xl? MnTWNVAh|ryP MUm0PEBp Mn2zSG1UVw>? MmjmTWM2OD13LkJihKnPxE1? M37nZlIzPjF2MkSz
MOLT-4 NGjuUGhHfW6ldHnvckBCe3OjeR?= NXz3NlVXOTBizszN MWWyOEBp MYDEUXNQ Ml7YRoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? M4XYOlIzPjF2MkSz
MOLT-4 NET6U3NHfW6ldHnvckBCe3OjeR?= NEXQSm416oDLzszN M{fmSVQhcA>? M1raUWROW09? NXXteI9FUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|NCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MYCyNlYyPDJ2Mx?=
CEM-R Mmj3SpVv[3Srb36gRZN{[Xl? NG\nZVM16oDLzszN M2TGZ|QhcA>? M3X2bWROW09? NVfTXmFGUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ NEGyO5IzOjZzNEK0Ny=>
CEM-S NYTXNpJJTnWwY4Tpc44hSXO|YYm= MUi05qCK|ryP NX\EeoNlPCCq Mn;sSG1UVw>? NUHySGJ7UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ NXzQW4VYOjJ4MUSyOFM>
HepG2 cell NUHleYhGU2mwYYPlJGF{e2G7 M4DHU|IxKM7:TR?= Mn23NlQhcA>? NV7ad2dKTE2VTx?= NGXwU|dFd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MlPmNlM4QTd|MUm=
HepG2 cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSyN|Ah|ryP NHSzPFUzPCCq MWDEUXNQ M2HqWWlvcGmkaYTzJINmdGxiZ4Lve5Rp NXPa[3FvOjN5OUezNVk>
HepG2 cell NXfXbGN7SXCxcITvd4l{KEG|c3H5 NWq3SWl7OjBizszN M37mWFI1KGh? MkjPSG1UVw>? NGPxXGhKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MVSyN|c6PzNzOR?=
GEO MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjJc2M2ODBibl2= MkLpO|IhcA>? NVzQdnd3TE2VTx?= NEDmN|RKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NVXBUpNJOjR3OEGyN|E>
CNE-1 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zfo1FOTBizszN M3TvVFk3KGh? M{XGdmROW09? MYDJR|UxRTJwOU[g{txO MWqyOVM{Pjl{NR?=
CNE-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTsW44yOCEQvF2= M4Duflk3KGh? NITXOVZFVVOR Mmj1TWM2OD12LkWzJO69VQ>? Mlj2NlU{OzZ7MkW=
HONE-1 NEfM[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnqNVAh|ryP NX\Fbnd5QTZiaB?= M1TUTmROW09? MlXGTWM2OD1|LkO3JO69VQ>? NHPZXJMzPTN|NkmyOS=>
SUNE-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpNVAh|ryP MVi5OkBp NVvUWlJlTE2VTx?= NWfhS5NTUUN3ME2wMlUzKM7:TR?= MYqyOVM{Pjl{NR?=
CNE-2 MYrGeY5kfGmxbjDBd5NigQ>? MWmxNEDPxE1? MmfrOFghcA>? NEnKPIhFVVOR NV\I[|k1UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NH\xNoczPTN|NkmyOS=>
HONE-1 NFzININHfW6ldHnvckBCe3OjeR?= MmLTNVAh|ryP MWm0PEBp NUX4[3dYTE2VTx?= M1;TPGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NGLne5ozPTN|NkmyOS=>
NEC8 NXT6NFNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DsXmlEPTB;MD6wPVY2OSEQvF2= MlPhV2FPT0WU
P12-ICHIKAWA M{TpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLnTWM2OD1yLkGxOlIh|ryP M4P1PHNCVkeHUh?=
MDA-MB-175-VII MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMUO3N|gh|ryP NFuxVm5USU6JRWK=
AsPC-1 M2LuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3fWlEPTB;MD6yNlEzOiEQvF2= NYHWfWo1W0GQR1XS
T47D MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzJTWM2OD1yLkK4NlUh|ryP NFPHZ2RUSU6JRWK=
HH NUDWTJpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH3TWM2OD1yLkOwNlg{KM7:TR?= NVPyZ|R1W0GQR1XS
MOLT-16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfwTmIyUUN3ME2wMlMxOzJizszN NGWzWpBUSU6JRWK=
ES5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Oyb2lEPTB;MD6zOFQ2PSEQvF2= MmXNV2FPT0WU
RS4-11 NUCyVVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvEbZFKSzVyPUCuN|Q3OSEQvF2= NXjBO3l5W0GQR1XS
KARPAS-45 NYfWVIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC4TWM2OD1yLkO3N|IyKM7:TR?= Mne3V2FPT0WU
NCI-H720 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1d2lEPTB;MD6zO|Y4QSEQvF2= MWnTRW5ITVJ?
H9 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nxUWlEPTB;MD6zPFg5OyEQvF2= MlHnV2FPT0WU
EFM-19 NIHqeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DcWlEPTB;MD60OFAyKM7:TR?= NHLIfWpUSU6JRWK=
SBC-1 M4\nTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjvWYdKSzVyPUCuOFQxOzVizszN Ml\QV2FPT0WU
A4-Fuk NFHZboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7senBKSzVyPUCuOFY5PjhizszN MkPLV2FPT0WU
NCI-H1563 NGq3dFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwNEixPFkh|ryP MmCyV2FPT0WU
HCC1419 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17USWlEPTB;MD60PFg6OiEQvF2= NWPJfZRjW0GQR1XS
H-EMC-SS NFnMbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPzTWM2OD1yLkS5PVM6KM7:TR?= MVjTRW5ITVJ?
BHT-101 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT6TWM2OD1yLkWyPVYyKM7:TR?= M2LPcHNCVkeHUh?=
IGROV-1 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LpTWlEPTB;MD61OVI1QSEQvF2= MXfTRW5ITVJ?
HGC-27 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjCWFFmUUN3ME2wMlU3Pzh|IN88US=> NYXaO5Z5W0GQR1XS
MDA-MB-361 M4izVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PZTWlEPTB;MD61O|c3OSEQvF2= NVztfo5WW0GQR1XS
KE-37 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmW2lEPTB;MD61PFI3KM7:TR?= MlPZV2FPT0WU
HCC70 M1[0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljCTWM2OD1yLkW5PFI4KM7:TR?= MV7TRW5ITVJ?
LNCaP-Clone-FGC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvIWVhCUUN3ME2wMlYyODR6IN88US=> NYfyV4xYW0GQR1XS
HAL-01 NWTUXG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELlXlRKSzVyPUCuOlIyOyEQvF2= NXm5SXR7W0GQR1XS
HT M{jxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ITWM2OD1yLk[zNlM6KM7:TR?= M2P3R3NCVkeHUh?=
MDA-MB-415 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:2TWM2OD1yLk[zOlI3KM7:TR?= MnXsV2FPT0WU
NOS-1 NXPPPJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDjTWM2OD1yLk[zO|I{KM7:TR?= M2DReHNCVkeHUh?=
DU-145 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwTWM2OD1yLk[0O|Q2KM7:TR?= Mk\FV2FPT0WU
OCUB-M M3qxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnzXGRKSzVyPUCuO|A6PjZizszN NV3OUlJ2W0GQR1XS
VA-ES-BJ MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD1yLkezNFI2KM7:TR?= NInSTnBUSU6JRWK=
J-RT3-T3-5 M1L3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF31c3BKSzVyPUCuO|Q1ODNizszN NGPO[VZUSU6JRWK=
MOLT-4 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwOVVxUUN3ME2wMlgxPTh{IN88US=> MljyV2FPT0WU
NB7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M372S2lEPTB;MD64NlQyOSEQvF2= MXzTRW5ITVJ?
L-363 NWPrfoJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr4ZWQ4UUN3ME2wMlg{PDR{IN88US=> M1\1S3NCVkeHUh?=
NKM-1 NV7YNGYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwOE[yOVMh|ryP MVnTRW5ITVJ?
HOP-92 NFvyVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LxTGlEPTB;MD64O|IzOyEQvF2= MofqV2FPT0WU
OAW-42 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7lVm9KSzVyPUCuPFg4OiEQvF2= NFfvRVJUSU6JRWK=
HuO9 NUmwc4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPISIlKSzVyPUCuPVI4PTFizszN MlvXV2FPT0WU
MFE-280 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETxVnNKSzVyPUCuPVY1PjVizszN NVXTVnVjW0GQR1XS
EM-2 NY\JeYQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3zPIpKSzVyPUCuPVc6OzlizszN M{j3XXNCVkeHUh?=
NCI-H520 NYPjS4s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr2Z2ZWUUN3ME2wMlk5PTl{IN88US=> M4n3fnNCVkeHUh?=
LB2241-RCC NIDuOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml32TWM2OD1yLkm5O|M1KM7:TR?= MmTyV2FPT0WU
SK-NEP-1 NV21e4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XWe2lEPTB;MT6xOFQ5PSEQvF2= MX7TRW5ITVJ?
LXF-289 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXx[lBqUUN3ME2xMlE4OTV4IN88US=> MX\TRW5ITVJ?
EPLC-272H M4XLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TicmlEPTB;MT6xO|I2PiEQvF2= M3TTenNCVkeHUh?=
COLO-684 NHX5OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LaXGlEPTB;MT6yN|czPSEQvF2= M2LSenNCVkeHUh?=
ES1 NXj2NmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjUSGJKSzVyPUGuNlQxPjVizszN NFrFS3ZUSU6JRWK=
DOHH-2 NVflWoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Hv[2lEPTB;MT6yPFIxOyEQvF2= NWrBPJZXW0GQR1XS
CTB-1 M{PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzTTmRKSzVyPUGuNlg6QSEQvF2= MnvoV2FPT0WU
G-401 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwMkm3PVUh|ryP NFnrR|BUSU6JRWK=
LoVo NEHUcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjkOYZKSzVyPUGuN|I2OzRizszN MnrZV2FPT0WU
Ramos-2G6-4C10 NGfyb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwM{O3NFEh|ryP MmHlV2FPT0WU
MFM-223 M3HnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q5[2lEPTB;MT6zOFQ3OSEQvF2= MUXTRW5ITVJ?
PA-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjFTWM2OD1zLkO1NlY2KM7:TR?= MmrPV2FPT0WU
697 NUPtVlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwM{e2NVYh|ryP NFL3bWdUSU6JRWK=
QIMR-WIL MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWroT5dNUUN3ME2xMlQ6OTF4IN88US=> NH\kSGFUSU6JRWK=
HOS MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNEm1OVgh|ryP Ml65V2FPT0WU
DMS-273 MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13JNGlEPTB;MT61NVk2QSEQvF2= NGLB[oxUSU6JRWK=
ME-180 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XqPWlEPTB;MT61Olg6OSEQvF2= MlSwV2FPT0WU
HCC2218 NGjuWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7TdG9KSzVyPUGuOlgzOjVizszN M2PYfHNCVkeHUh?=
CAL-54 NWTQcXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknRTWM2OD1zLkexNlQzKM7:TR?= MlqzV2FPT0WU
OMC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\icmJlUUN3ME2xMlc1Pjd5IN88US=> NXnlVWhVW0GQR1XS
COR-L105 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPb4xrUUN3ME2xMlc6PzN5IN88US=> Mm\XV2FPT0WU
BV-173 NFHFdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOzV4xKSzVyPUGuPFExPzRizszN MnTpV2FPT0WU
RKO MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXUSFlyUUN3ME2xMlg4OTBzIN88US=> M2\TSXNCVkeHUh?=
SNU-387 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwOEi0NFYh|ryP NWmzN4tSW0GQR1XS
SW1088 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r1b2lEPTB;MT65OFYxPiEQvF2= M1XoPXNCVkeHUh?=
Hs-578-T M3Tm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\aW45TUUN3ME2yMlEyPDN|IN88US=> M{LSZXNCVkeHUh?=
OC-314 M{nE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMUWwPFYh|ryP NYT0OIQzW0GQR1XS
RMG-I M1PocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rp[2lEPTB;Mj6xOlM6QCEQvF2= MWTTRW5ITVJ?
NCI-H1395 NXq3UHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HaWWlEPTB;Mj6xPFA6OSEQvF2= NX;RWZA5W0GQR1XS
GAMG NI\leXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYWWpmUUN3ME2yMlI{QDR3IN88US=> M1nEWnNCVkeHUh?=
LB1047-RCC NXTQU|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPJcJFKSzVyPUKuNlQ{OTdizszN NHm1dWZUSU6JRWK=
MN-60 M2XES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfITWM2OD1{LkK5PVI{KM7:TR?= NIjjdZhUSU6JRWK=
OAW-28 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLpT3c3UUN3ME2yMlI6QTVzIN88US=> MUHTRW5ITVJ?
NCI-H2228 NH\1bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwM{G1OVIh|ryP M4rTbHNCVkeHUh?=
ABC-1 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwM{OyOVMh|ryP MmTxV2FPT0WU
LS-513 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD4XGFQUUN3ME2yMlM{PDh2IN88US=> NXXTfYNkW0GQR1XS
KS-1 NInjUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\QemlEPTB;Mj6zPFE6OSEQvF2= NUS4OmJpW0GQR1XS
NB69 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUZldKSzVyPUKuN|g6QDNizszN NXnxcmdZW0GQR1XS
VM-CUB-1 NV7tcZM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHWOJlKSzVyPUKuN|kxQDNizszN M1HRSnNCVkeHUh?=
D-423MG M1XtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Xco03UUN3ME2yMlQyODR2IN88US=> NHHSfohUSU6JRWK=
EW-18 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4OGlEPTB;Mj60NVk{QSEQvF2= NWLpXmdTW0GQR1XS
YH-13 M{P1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfxVmNKSzVyPUKuOFYyPTNizszN NH\lc|dUSU6JRWK=
T-24 NEHmN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnHbHJKSzVyPUKuOFc5QDFizszN MX\TRW5ITVJ?
ES8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KZVZOUUN3ME2yMlQ6Ojh5IN88US=> M4nacnNCVkeHUh?=
ES3 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{CxRWlEPTB;Mj60PVc2QSEQvF2= M2LBXnNCVkeHUh?=
RXF393 NIDqOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLONmNkUUN3ME2yMlYxPDh5IN88US=> NVzlWHpoW0GQR1XS
RPMI-8226 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDRTWM2OD1{Lk[yPVU{KM7:TR?= M4XjNnNCVkeHUh?=
AGS MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LUWWlEPTB;Mj63NlE{PyEQvF2= NECzdFRUSU6JRWK=
HCC1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7yTWM2OD1{Lke1NVg4KM7:TR?= NXzQNo9kW0GQR1XS
MV-4-11 NYHsd4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;HTWM2OD1{Lke1NlY3KM7:TR?= NXHSNFNNW0GQR1XS
A204 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HRemlEPTB;Mj64N|g4OiEQvF2= M3vwZnNCVkeHUh?=
MCF7 NVzOdnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwOE[xNVch|ryP NFfYNJlUSU6JRWK=
SNU-423 NIXVWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fMbGlEPTB;Mj64PVI1OiEQvF2= NFT5OnBUSU6JRWK=
NCI-H1048 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwOU[4OlUh|ryP MWDTRW5ITVJ?
GR-ST NHPrSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7JSG1KSzVyPUOuNFQ3OTFizszN MkTGV2FPT0WU
EoL-1- MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H5TmlEPTB;Mz6wO|A2QCEQvF2= Ml\XV2FPT0WU
HuH-7 NXX0W25CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f1ZWlEPTB;Mz6wPVQ3PCEQvF2= MnraV2FPT0WU
OS-RC-2 NYnPTIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDCTWM2OD1|LkGxNVkh|ryP MV\TRW5ITVJ?
EW-3 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jDfmlEPTB;Mz6xPVUzQSEQvF2= NVTXeYFDW0GQR1XS
NCI-H747 NEjt[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PCSmlEPTB;Mz6yNFY6PCEQvF2= M4O2XHNCVkeHUh?=
EW-16 NHfuN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwMkG4O|kh|ryP MoXTV2FPT0WU
DOK NVntcI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPsSVhKSzVyPUOuNlI5PTlizszN MULTRW5ITVJ?
HCC2157 NYrQe5dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPyO2RKSzVyPUOuN|gyPzlizszN MoSyV2FPT0WU
OVCAR-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNwNEC3PFYh|ryP MUnTRW5ITVJ?
NCI-H1623 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1|LkSxNlI1KM7:TR?= MXfTRW5ITVJ?
H4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInjPWFKSzVyPUOuOFU3OjZizszN NUXXSGl7W0GQR1XS
SW1710 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPLTWM2OD1|LkS2Olc5KM7:TR?= NXnoVXRHW0GQR1XS
RT-112 NUWyN2JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCeZJKSzVyPUOuOVI{QDhizszN MmPlV2FPT0WU
DMS-114 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwNkKyO|gh|ryP MWTTRW5ITVJ?
AN3-CA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vXVGlEPTB;Mz62NlQ2PiEQvF2= NV;sRZdHW0GQR1XS
KNS-62 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXETWM2OD1|Lk[zN|M5KM7:TR?= NHPxcpRUSU6JRWK=
SJRH30 M3HLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXldGxZUUN3ME2zMlY6OTJ{IN88US=> MkjWV2FPT0WU
G-402 M1K2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXIR5dKSzVyPUOuO|A4OTFizszN NGjEWZJUSU6JRWK=
MHH-PREB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfKTWM2OD1|LkeyNFM5KM7:TR?= NV3uVGgxW0GQR1XS
P30-OHK M1fWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrETWM2OD1|LkiwPVc3KM7:TR?= NYm1ZlUyW0GQR1XS
RVH-421 NH\zdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmxcno2UUN3ME2zMlgyPzh6IN88US=> NUO0N3JZW0GQR1XS
LU-134-A NYnOTJlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjzUlJKSzVyPUOuPFg1OjhizszN NFLnbYVUSU6JRWK=
ECC10 NF75eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqyN4ZmUUN3ME2zMlk{PjJ{IN88US=> NVXaT5ZjW0GQR1XS
TGW M2nZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj6TWM2OD12LkCyN|A2KM7:TR?= MmnMV2FPT0WU
MLMA MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPQTWM2OD12LkCyPVY3KM7:TR?= M1HwXnNCVkeHUh?=
SCC-25 NGP1VWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M171UGlEPTB;ND6wOlU3PiEQvF2= M3fhTXNCVkeHUh?=
TYK-nu MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPkSpBKSzVyPUSuNFk2OzRizszN M3XmNnNCVkeHUh?=
LAMA-84 NG[3dHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1foZKSzVyPUSuNVQyQTFizszN NWrmPYJqW0GQR1XS
Calu-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwMkS0NVYh|ryP NF\3UWpUSU6JRWK=
NCI-H460 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnHTWM2OD12LkK2OFQ{KM7:TR?= NEnR[IhUSU6JRWK=
EGI-1 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn64TWM2OD12LkO3O|c5KM7:TR?= MWLTRW5ITVJ?
NCI-H292 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGzTWdKSzVyPUSuN|gyPDZizszN MlPNV2FPT0WU
HCE-T M2TlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD12LkSxOVc6KM7:TR?= NVT3TIVEW0GQR1XS
EW-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW5NIFKSzVyPUSuOFE5OzhizszN M17zVXNCVkeHUh?=
ATN-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz4TWM2OD12LkS0N|A1KM7:TR?= MoDWV2FPT0WU
NB5 NFnGVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyXoJKSzVyPUSuOVM3QTdizszN NUjUVVV2W0GQR1XS
KLE M17YTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTRwN{CxPVgh|ryP MoXkV2FPT0WU
CAL-39 NXq4Xo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzaTHpIUUN3ME20MlczOTR4IN88US=> M172SXNCVkeHUh?=
TI-73 NVW3VZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5fmd2UUN3ME20MlgxPjB7IN88US=> MXXTRW5ITVJ?
HO-1-N-1 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXU[JhRUUN3ME20Mlk1OiEQvF2= NYHp[VdzW0GQR1XS
786-0 NY\sT496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofTTWM2OD12Lkm0Olc{KM7:TR?= NEHWNIJUSU6JRWK=
SK-N-DZ NWrYW3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjZS4dKSzVyPUSuPVYyPDJizszN Mkn2V2FPT0WU
NCI-H446 M3vQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETMW5lKSzVyPUWuNlAxODlizszN M3LPOnNCVkeHUh?=
ETK-1 M{Xrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDUNZhKSzVyPUWuNlEyPjVizszN MVnTRW5ITVJ?
BT-20 M{HUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DxdGlEPTB;NT6yNVM2OyEQvF2= M3PwSXNCVkeHUh?=
MEL-HO M2TxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;KTWM2OD13LkO3N|M3KM7:TR?= NEWwVo1USU6JRWK=
CAL-27 NVXpZYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XhWmlEPTB;NT60OlM{QSEQvF2= NE\HOZJUSU6JRWK=
SW872 M{GyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVwNUm0Nlgh|ryP M4rST3NCVkeHUh?=
RPMI-2650 NYnOfW95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XIW2lEPTB;NT62OlE6QSEQvF2= NUTwTpNSW0GQR1XS
PFSK-1 NH;sU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQ[FlMUUN3ME21MlczPzN{IN88US=> NWe0bYI5W0GQR1XS
SF295 NFvpW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXizW4l{UUN3ME21MlgxPjN|IN88US=> M{fJT3NCVkeHUh?=
Becker MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLuTWM2OD13Lki2OFczKM7:TR?= M1fDPXNCVkeHUh?=
Saos-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDVfJpKSzVyPUWuPFY2OyEQvF2= MXzTRW5ITVJ?
SK-OV-3 NGLTPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjLemp7UUN3ME21Mlk6QDF4IN88US=> MnPzV2FPT0WU
VMRC-RCZ NH[w[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOxTnJDUUN3ME22MlA5Pzd|IN88US=> NYHiWFloW0GQR1XS
EW-22 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\OWGlEPTB;Nj6xPVY1QSEQvF2= NXXvN4lpW0GQR1XS
BT-474 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwMkOzJO69VQ>? NESzXG5USU6JRWK=
BFTC-909 M3jYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\yTWM2OD14LkOwN|Q2KM7:TR?= M2nrPXNCVkeHUh?=
NB12 NGT6cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD14LkO5NFcyKM7:TR?= MorRV2FPT0WU
D-263MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon6TWM2OD14LkS1NVY6KM7:TR?= NV3LfoJSW0GQR1XS
SNB75 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jWdmlEPTB;Nj62NFE1OyEQvF2= NUXDRm1PW0GQR1XS
A704 NHyxSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTZwNkOwOkDPxE1? MWfTRW5ITVJ?
NCI-H1693 NUjsXIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7DeY9KSzVyPU[uOlM3ODRizszN MlWxV2FPT0WU
LN-405 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjCcm9KSzVyPU[uO|k3PzJizszN MULTRW5ITVJ?
CHL-1 NUfiWplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwOECwO|kh|ryP M1vLRXNCVkeHUh?=
A498 NULofGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZwOEG5OlEh|ryP NYjET4g4W0GQR1XS
TE-12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTZwOEO4NVch|ryP M1LObHNCVkeHUh?=
TE-6 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nIUGlEPTB;Nj65N|A{QCEQvF2= MWnTRW5ITVJ?
AU565 NIP3T5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD14Lkm2PVU4KM7:TR?= NV6wbXlIW0GQR1XS
RD NYrCeW15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrkTWM2OD14Lkm4Nlg1KM7:TR?= M2DKbnNCVkeHUh?=
SW1463 NU\ibYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzveJBKSzVyPUeuNVEyPjhizszN M1uwUnNCVkeHUh?=
LU-99A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjaTWM2OD15LkG0N|IzKM7:TR?= M2DYNHNCVkeHUh?=
NCI-H28 NWfJcpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwMkmyOEDPxE1? MVPTRW5ITVJ?
MC-IXC Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LxW2lEPTB;Nz60PFU4PiEQvF2= NHzNWYlUSU6JRWK=
GP5d M3HOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHiTWM2OD15LkS4O|Y1KM7:TR?= MoPyV2FPT0WU
GB-1 NVrO[oJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT1cVVKSzVyPUeuOVQ5ODRizszN MYDTRW5ITVJ?
CAL-33 NYrsPW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTdwNk[yN|Mh|ryP MkHyV2FPT0WU
MSTO-211H MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD15Lk[3N|M3KM7:TR?= MmW0V2FPT0WU
TE-5 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nxN2lEPTB;Nz63PVM{PCEQvF2= MXHTRW5ITVJ?
D-566MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi4eZJMUUN3ME24MlA1PDJ7IN88US=> NUe5fGJYW0GQR1XS
JVM-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRThwMUWyOlgh|ryP MmnlV2FPT0WU
T98G MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS5OXNKSzVyPUiuNVgxPjdizszN NXrxSZdHW0GQR1XS
HCC1954 NIPOR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRThwNEWxNFQh|ryP M{PRV3NCVkeHUh?=
SF126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrEN3ZrUUN3ME24MlQ2QTN4IN88US=> MUTTRW5ITVJ?
LB996-RCC NF7afldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5VnZKSzVyPUiuOVMzPTdizszN NYLub3hHW0GQR1XS
SKG-IIIa NEG3V2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvOnFKSzVyPUiuOlMxPjlizszN NWjMeVRWW0GQR1XS
NCI-SNU-1 NELpT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\TZWlEPTB;OD62OFY1OyEQvF2= NFvP[ZRUSU6JRWK=
LB771-HNC NH3lcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHqV5hzUUN3ME24MlY1Pjl4IN88US=> M{fDbnNCVkeHUh?=
SCC-4 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruR5lKSzVyPUiuOlgzOTlizszN NGTDWmdUSU6JRWK=
CAMA-1 M1nwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2bGlEPTB;OD63O|E1PiEQvF2= NEHjW5FUSU6JRWK=
D-502MG Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;qTWM2OD16Lke4OlI6KM7:TR?= M4nibHNCVkeHUh?=
ESS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4frZ2lEPTB;OD64PFcxPCEQvF2= MWPTRW5ITVJ?
HEC-1 M4fESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\jVJY6UUN3ME24Mlg6QDZ4IN88US=> NG\nbIVUSU6JRWK=
NB10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnCTWM2OD17LkCyNlI1KM7:TR?= MWLTRW5ITVJ?
8505C NF7keJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTlwMESyN|Ih|ryP NHjJcm5USU6JRWK=
EFO-27 NGjMfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD17LkG2OFEzKM7:TR?= NXjNclRzW0GQR1XS
HN NETjVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT5TWM2OD17LkG2OlI5KM7:TR?= NWTIcGxVW0GQR1XS
DSH1 NXfQOJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXofXZKSzVyPUmuNlA5PyEQvF2= MXXTRW5ITVJ?
NBsusSR NE\yZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorSTWM2OD17LkK3OFAzKM7:TR?= NYniVlVJW0GQR1XS
LS-123 NIDRb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HEUmlEPTB;OT6zNVc3OSEQvF2= MV7TRW5ITVJ?
SHP-77 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jCdGlEPTB;OT6zPVk{PSEQvF2= MVrTRW5ITVJ?
ACN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHGTWM2OD17LkWzNlc4KM7:TR?= MUPTRW5ITVJ?
U251 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\nRoltUUN3ME25MlY2PTR2IN88US=> MlnEV2FPT0WU
A431 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXJV|l{UUN3ME25MlgxOjN6IN88US=> M{L5cXNCVkeHUh?=
5637 M3vtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXCXY4{UUN3ME25Mlg1QTh2IN88US=> NETNfJRUSU6JRWK=
MDA-MB-157 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRN2lEPTB;OT65Nlg4QCEQvF2= NIS5SXhUSU6JRWK=
A101D MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HwTmlEPTB;OT65PVk4PCEQvF2= MVLTRW5ITVJ?
YKG-1 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX6TWM2OD1zMD6yNFA3KM7:TR?= NYHrSnExW0GQR1XS
LAN-6 NX7Gcnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLjO4NQUUN3ME2xNE4zOTZ2IN88US=> NYXLVnZvW0GQR1XS
OVCAR-5 M2q2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjVN5VkUUN3ME2xNE4zPDN|IN88US=> M1e5eXNCVkeHUh?=
A549 NH[3PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFyLkO5O|Mh|ryP MoXqV2FPT0WU
no-11 NW\QW5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHqbXdKSzVyPUGwMlQ{PTNizszN MVPTRW5ITVJ?
SF539 M{C0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDYSY9KSzVyPUGwMlkxPDFizszN M3W2Z3NCVkeHUh?=
A388 M{CxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPNOo9KSzVyPUGxMlM5QTdizszN M1jqZXNCVkeHUh?=
DEL NUnlRot6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFzLkSyOEDPxE1? MoTIV2FPT0WU
SW954 NHm4bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFzLkS2Olgh|ryP M{\BRXNCVkeHUh?=
TK10 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzQTWM2OD1zMT61NlcyKM7:TR?= M3HQNHNCVkeHUh?=
SW756 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmcoZKSzVyPUGxMlUzQTRizszN MV7TRW5ITVJ?
PC-3 M3r0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\MTWM2OD1zMT61O|Y1KM7:TR?= NHjGc3VUSU6JRWK=
ONS-76 NGDqRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLk[zOkDPxE1? NIjEVpBUSU6JRWK=
A427 NV23b2tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFzLkewPVMh|ryP M{jhZ3NCVkeHUh?=
MEG-01 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDXW3dVUUN3ME2xNU44PTB7IN88US=> NGjXTXJUSU6JRWK=
BB30-HNC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFzLke5PFIh|ryP MVnTRW5ITVJ?
NCI-H1299 NXfuTphVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jSOmlEPTB;MUGuPFA6OyEQvF2= NFXhTm9USU6JRWK=
GCT NUfLVHR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjUdm9KSzVyPUGxMlgzOjhizszN NVfLVZFLW0GQR1XS
D-247MG NUjE[4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHvTWM2OD1zMT65OlY{KM7:TR?= MY\TRW5ITVJ?
CFPAC-1 M1z5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2UpFKSzVyPUGxMlk4QDJizszN M4HhcXNCVkeHUh?=
EKVX NV\rNJlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojkTWM2OD1zMj6wN|E{KM7:TR?= NXfpfY9sW0GQR1XS
CAL-51 NHWxepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF{LkC3NVYh|ryP MU\TRW5ITVJ?
BB49-HNC NHrBWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnYTWM2OD1zMj6xNVc4KM7:TR?= MXTTRW5ITVJ?
RPMI-7951 NFfXZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfyRodpUUN3ME2xNk4yQDV2IN88US=> NIfjU|VUSU6JRWK=
RH-1 M{PQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGR2lEPTB;MUKuNlE5PCEQvF2= M3PKfXNCVkeHUh?=
BCPAP M13NSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nUVWlEPTB;MUKuOFc1QSEQvF2= MXnTRW5ITVJ?
GCIY M37oVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TL[GlEPTB;MUKuOVIxQSEQvF2= NWjzbYV4W0GQR1XS
KNS-81-FD M{ftR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF{LkW4Olkh|ryP NGDIO2RUSU6JRWK=
KYSE-140 NHW0SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3TWM2OD1zMj64OVk2KM7:TR?= NUTNOWpzW0GQR1XS
Ca-Ski MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF{LkmwOFEh|ryP MnPSV2FPT0WU
TGBC1TKB MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;kNplnUUN3ME2xNk46OTF3IN88US=> M3nROXNCVkeHUh?=
HCC1187 NX33U2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF|LkG5NVIh|ryP NHuzb4hUSU6JRWK=
SJSA-1 NF[2OYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXQRpVzUUN3ME2xN{4zOzJ5IN88US=> NHz5SmhUSU6JRWK=
CTV-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXReHFKSzVyPUGzMlM1PSEQvF2= MmDVV2FPT0WU
WM-115 M4HMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF|Lk[0PFMh|ryP NFnyeFFUSU6JRWK=
CHP-212 NWq5d4FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF|Lkm3N|kh|ryP M2LVTnNCVkeHUh?=
SCC-15 NX7VUWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjUTWM2OD1zMz65O|c2KM7:TR?= Ml\2V2FPT0WU
BPH-1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T3WGlEPTB;MUSuNVY3PCEQvF2= MWLTRW5ITVJ?
SW780 NW\ibmdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NeGVKSzVyPUG0MlUxOjVizszN MVXTRW5ITVJ?
NCI-H2291 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF2LkW4O|gh|ryP MnzrV2FPT0WU
JEG-3 NIKxRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pZZRKSzVyPUG0MlY{OjZizszN NUDJVGx1W0GQR1XS
CAL-120 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnYTWM2OD1zND63NFI4KM7:TR?= MWDTRW5ITVJ?
NCI-H23 M2jPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmzTWM2OD1zND63PVk4KM7:TR?= NFG4XWJUSU6JRWK=
MS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF2Lkm2NVEh|ryP MmTCV2FPT0WU
PC-14 NX3KbldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KxTmlEPTB;MUSuPVY2PCEQvF2= MXnTRW5ITVJ?
D-283MED NIm3cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT6TWM2OD1zNT6wNVEyKM7:TR?= MWnTRW5ITVJ?
OE19 M{n1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL1TWM2OD1zNT6xOVQyKM7:TR?= NUP0RYlQW0GQR1XS
CAS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF3LkSxPFQh|ryP NIrnOHpUSU6JRWK=
NCI-H727 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle4TWM2OD1zNT60NlIyKM7:TR?= NXXPfY1UW0GQR1XS
SiHa MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33jV2lEPTB;MUWuO|U6PCEQvF2= MWTTRW5ITVJ?
BFTC-905 M4C2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF3Lke2PVQh|ryP NXrqVVhNW0GQR1XS
MDA-MB-453 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jPXBQUUN3ME2xOk4yPjR{IN88US=> NWX0XY51W0GQR1XS
HuP-T3 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1Z2lEPTB;MU[uOlM4OyEQvF2= MnPBV2FPT0WU
SK-LU-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF4Lk[5OVYh|ryP NWHRZVZ6W0GQR1XS
Detroit562 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nRVGlEPTB;MU[uO|MyQCEQvF2= NWL4OndEW0GQR1XS
HCC1569 M2\yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJVFF6UUN3ME2xOk45OzN5IN88US=> Mn[5V2FPT0WU
SK-MES-1 NUjFUpZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF4Lki0NVkh|ryP Mn[3V2FPT0WU
BB65-RCC MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\lZ2RKSzVyPUG3MlA1PzlizszN M3r4S3NCVkeHUh?=
LOXIMVI M1PJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO4N3JEUUN3ME2xO{4xPzB5IN88US=> NG[5eXlUSU6JRWK=
SW1783 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1zNz6xNlgh|ryP NYPSSo9QW0GQR1XS
NH-12 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ThWWlEPTB;MUeuN|MxOyEQvF2= M4rURnNCVkeHUh?=
UACC-257 NVjZdpFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHeHFKSzVyPUG3MlU2OTJizszN M33YNHNCVkeHUh?=
KOSC-2 NHPSVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF5Lk[3OVch|ryP NYHiZ3k1W0GQR1XS
KG-1 NWHnbpZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fsfWlEPTB;MUeuOlk{PyEQvF2= NFHGe3pUSU6JRWK=
M059J MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fremlEPTB;MUeuO|A{KM7:TR?= MoC0V2FPT0WU
MHH-NB-11 NYrtbmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUbmlEPTB;MUeuPVY4OyEQvF2= NIHkTVlUSU6JRWK=
EW-1 M4LYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[zTWM2OD1zOD6xN|gzKM7:TR?= MYTTRW5ITVJ?
CAL-85-1 NFruNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6LkKzOVch|ryP MkDEV2FPT0WU
639-V M{XvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXweWVKSzVyPUG4MlM{PTRizszN NYDYdZQ3W0GQR1XS
C32 M{DVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvHU4lJUUN3ME2xPE41PzJ5IN88US=> MkHmV2FPT0WU
KM-H2 NUPO[FdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXrN4V2UUN3ME2xPE42OjN{IN88US=> NVvZT2tmW0GQR1XS
A253 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLme3BTUUN3ME2xPE44Ojh4IN88US=> NH63bmhUSU6JRWK=
NCI-N87 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHjTWM2OD1zOD65NFA5KM7:TR?= NYezfGc{W0GQR1XS
8-MG-BA NHXENXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYW3lKSzVyPUG5MlA3PDZizszN NEi0U|RUSU6JRWK=
GI-ME-N NETGU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDVNJZSUUN3ME2xPU4yPTR4IN88US=> NF3V[YtUSU6JRWK=
8305C NX;xfpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF7LkKyPFYh|ryP NYDFXGpvW0GQR1XS
TE-8 M3jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHVR3MzUUN3ME2xPU4{ODJ2IN88US=> NX\xXZJkW0GQR1XS
KYSE-270 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ufGlEPTB;MkCuNFIyPyEQvF2= MUTTRW5ITVJ?
HL-60 M1HafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJyLkC5OFEh|ryP NGCxRohUSU6JRWK=
Mo-T M4PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PnR2lEPTB;MkCuNVY3PSEQvF2= NIDrTFVUSU6JRWK=
NCI-H1355 NWHwSWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrqS5lKSzVyPUKwMlM{PzRizszN NW\id5B3W0GQR1XS
HT-1080 NVXmZXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M322RWlEPTB;MkCuOVQ6PyEQvF2= NWj6foxqW0GQR1XS
MIA-PaCa-2 NFniUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1{MD62PFg{KM7:TR?= MmLCV2FPT0WU
NCI-H441 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzxTWM2OD1{MD63N|c6KM7:TR?= NXfBVYI1W0GQR1XS
LCLC-97TM1 M1nsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni2TWM2OD1{MD64NVM1KM7:TR?= NXvrVFBWW0GQR1XS
HT-3 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTDVIpKSzVyPUKxMlU3OzFizszN NYnFVJViW0GQR1XS
22RV1 NGHVXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fERmlEPTB;MkGuOVY5PSEQvF2= Mn\sV2FPT0WU
LK-2 M1XhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJzLkW5OVMh|ryP NGLNRVhUSU6JRWK=
CW-2 M2HaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fUUWlEPTB;MkGuOlA3QSEQvF2= MWDTRW5ITVJ?
KYSE-510 NGT3VoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ETWM2OD1{MT62NFk2KM7:TR?= NVT6bFRXW0GQR1XS
CGTH-W-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2zcoRoUUN3ME2yNU44OTZ4IN88US=> M2nZV3NCVkeHUh?=
NCI-H661 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ{LkCzOEDPxE1? MV\TRW5ITVJ?
KU-19-19 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD1{Mj6xOlk4KM7:TR?= MVLTRW5ITVJ?
NCI-H2122 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL5Z|BKSzVyPUKyMlI1OzJizszN MUjTRW5ITVJ?
NCI-H526 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHw[VNCUUN3ME2yNk4{QDl3IN88US=> M3SxU3NCVkeHUh?=
NCI-H1650 NHnQU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDnNGxjUUN3ME2yNk44PjRizszN MUTTRW5ITVJ?
AM-38 M3rOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrlR2JzUUN3ME2yNk45Pjh7IN88US=> MV7TRW5ITVJ?
NCI-H2405 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT2[ZRRUUN3ME2yN{4zPTN|IN88US=> Mm\RV2FPT0WU
M14 M1H3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ|LkSwPFgh|ryP MXfTRW5ITVJ?
ES4 NGnBcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ|LkSyN|Ih|ryP NIrWb4hUSU6JRWK=
DJM-1 NHXxUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK1fI1KSzVyPUKzMlUzOzRizszN NV;LbGxnW0GQR1XS
S-117 NXeyPI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:zTWM2OD1{Mz63OlUyKM7:TR?= NXn2dFlnW0GQR1XS
MZ2-MEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jTVGlEPTB;MkOuO|c2QSEQvF2= NUHuOJFPW0GQR1XS
SK-MEL-2 NHjBW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnuOnlMUUN3ME2yN{45OTN|IN88US=> NVTI[FJkW0GQR1XS
HCC1806 M1PPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ|Lki3NFkh|ryP Mm\5V2FPT0WU
NMC-G1 NUHiRVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ2LkKyNlYh|ryP M1fYOHNCVkeHUh?=
DK-MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Ha[GlEPTB;MkSuNlk1KM7:TR?= NHHvR4lUSU6JRWK=
SK-N-FI M3;iSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37iV2lEPTB;MkSuN|MxOiEQvF2= MWXTRW5ITVJ?
KINGS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlqwTWM2OD1{ND60PFc1KM7:TR?= MUXTRW5ITVJ?
HCC2998 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX3WHNKSzVyPUK0MlQ5QDVizszN Mlr2V2FPT0WU
ALL-PO NF7lSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0WWlEPTB;MkSuOlE6KM7:TR?= MnrUV2FPT0WU
MPP-89 M2P2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ3LkC0OVgh|ryP NYG5NW9HW0GQR1XS
NCI-H2342 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XPfWlEPTB;MkWuNVk2OyEQvF2= MkPxV2FPT0WU
TE-1 NGqzOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX1OVJKSzVyPUK1MlM2PjNizszN NXTrdY5EW0GQR1XS
RH-18 M1TLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjrR2FKSzVyPUK1MlU6OThizszN MnHwV2FPT0WU
HT-1376 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPGWVBKSzVyPUK1MlY1PjVizszN NVW2Xo1MW0GQR1XS
U-2-OS MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT3bm1KSzVyPUK1MlY5QDhizszN M17TS3NCVkeHUh?=
BT-549 NFXiR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmR2VKSzVyPUK1MlkxOTFizszN MonaV2FPT0WU
NCI-H1755 M{eyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XlbmlEPTB;MkWuPVk1PSEQvF2= MV3TRW5ITVJ?
EW-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYTWM2OD1{Nj6wNlc1KM7:TR?= NVjmPWd3W0GQR1XS
NB13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ4LkC5OFkh|ryP NXvaXFBMW0GQR1XS
NUGC-3 NG\OV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW4SWFKSzVyPUK2MlIyODNizszN NHjKfZNUSU6JRWK=
GMS-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ4LkKzOVMh|ryP Ml7hV2FPT0WU
CHP-134 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHuRph3UUN3ME2yOk4{QDZ5IN88US=> NXfufnRGW0GQR1XS
SW962 M{flV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTaNVYxUUN3ME2yOk42ODJzIN88US=> M1f2T3NCVkeHUh?=
SNU-449 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33hUGlEPTB;MkeuNFgxOyEQvF2= M1jBTXNCVkeHUh?=
HuP-T4 M4W3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ5LkC4O|kh|ryP NGXsTmlUSU6JRWK=
SW948 NUX3VGp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ5LkGzOFQh|ryP MoPpV2FPT0WU
NCI-H226 M2fN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\EdW1pUUN3ME2yO{41PTd6IN88US=> NF3Ceo5USU6JRWK=
SK-PN-DW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ5Lk[wNVIh|ryP M2PzenNCVkeHUh?=
GI-1 NF7XcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETmSYlKSzVyPUK3MlczOSEQvF2= NYW4So0yW0GQR1XS
CAL-12T MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ6LkGxNVIh|ryP MUHTRW5ITVJ?
YAPC M3vuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\JTWM2OD1{OD6yOVY1KM7:TR?= M3vmN3NCVkeHUh?=
SNU-C2B MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXyRmpXUUN3ME2yPE4zQTZ2IN88US=> NUDheoFHW0GQR1XS
RCC10RGB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7J[ppKSzVyPUK4MlU1OTdizszN Mk[5V2FPT0WU
ES7 M4jyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ7LkG0OlUh|ryP MWrTRW5ITVJ?
PANC-03-27 NWLzW4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIey[2xKSzVyPUK5MlQ1PCEQvF2= NV;UTlV5W0GQR1XS
ES6 NX\pN45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OybWlEPTB;MkmuPFE2PyEQvF2= NUPyTYdMW0GQR1XS
HT-1197 NEOzVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNyLkC1PVgh|ryP NUXkeFk6W0GQR1XS
ZR-75-30 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNyLkKzPFMh|ryP Mof2V2FPT0WU
DB NYPXbYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK3T4lpUUN3ME2zNE41QTR{IN88US=> MlLrV2FPT0WU
OCI-AML2 NVK1e2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PzVGlEPTB;M{GuNFY6KM7:TR?= M{fDWXNCVkeHUh?=
NCI-H2170 NUnnfnQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4N2pKSzVyPUOxMlg2OTZizszN NH7VcHNUSU6JRWK=
IST-MES1 NHzESVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLnTWM2OD1|Mj6yPFk4KM7:TR?= M4n6fnNCVkeHUh?=
769-P NXfEe3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu1TWM2OD1|Mj6zOlQyKM7:TR?= MUHTRW5ITVJ?
COR-L23 NEXRfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DEbWlEPTB;M{KuPVA4OyEQvF2= NGXEb4xUSU6JRWK=
SW626 NVnEUFFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\wTWM2OD1|Mz6xO|c3KM7:TR?= M2mwVHNCVkeHUh?=
LU-139 M3;C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrEbnZHUUN3ME2zN{43PjB3IN88US=> NHjMPHpUSU6JRWK=
HT-144 NWmwRYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTN|Lki2N{DPxE1? M{\ZcnNCVkeHUh?=
CaR-1 M4m2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD6e5pGUUN3ME2zN{46QDJ{IN88US=> M3ftd3NCVkeHUh?=
OE33 M4DlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\DW|RWUUN3ME2zOE4zQDV3IN88US=> MXXTRW5ITVJ?
COLO-800 NXLtN4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn6TWM2OD1|ND6zOlQ4KM7:TR?= NITCXodUSU6JRWK=
NB14 M{jzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\aOmlEPTB;M{SuOFY5PCEQvF2= MlHZV2FPT0WU
KURAMOCHI NY\MUlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTlZ|NKSzVyPUO2MlEyQThizszN MmXuV2FPT0WU
SW48 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN4LkK0O|Qh|ryP M1izXXNCVkeHUh?=
Daoy NXuzc4RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD1|Nj62OVM5KM7:TR?= M4TGb3NCVkeHUh?=
TGBC24TKB NEjTco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\zVFNKSzVyPUO2MlY4KM7:TR?= M4r4WnNCVkeHUh?=
DU-4475 M3nNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX5TWM2OD1|Nj65NFM{KM7:TR?= Mo\WV2FPT0WU
SW1417 NUTFeXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mzV2lEPTB;M{iuNFU2OiEQvF2= M2fKTnNCVkeHUh?=
EFO-21 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD1|OD65N|Q6KM7:TR?= M37xeHNCVkeHUh?=
MG-63 M3nNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTsb|J{UUN3ME2zPU4{PDJ2IN88US=> NV;mOmoxW0GQR1XS
LC-2-ad MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj4TWM2OD1|OT61OVEzKM7:TR?= MmDFV2FPT0WU
NOMO-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PHdWlEPTB;M{muPFI4PCEQvF2= Mo[5V2FPT0WU
COLO-741 NXLPN4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDWTGFKSzVyPUSwMlE{ODRizszN NVrOUWRkW0GQR1XS
BxPC-3 NUPH[YJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMeGlPUUN3ME20NE42Pjh4IN88US=> M2fVWHNCVkeHUh?=
HSC-2 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyzPIplUUN3ME20NE46OTF|IN88US=> MXTTRW5ITVJ?
UMC-11 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fOdGlEPTB;NEGuNlY{KM7:TR?= NGCwfHpUSU6JRWK=
HCC1937 NIjIOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP2TWM2OD12Mj63PFQ{KM7:TR?= MXfTRW5ITVJ?
Calu-6 M{XHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2TWM2OD12Mz6yN|gzKM7:TR?= M1f3[3NCVkeHUh?=
NCI-H1573 M2Dtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm2SoNHUUN3ME20N{4{PDd5IN88US=> M1XYV3NCVkeHUh?=
SK-N-AS M3\NNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR|Lk[wNVkh|ryP NYrSc25LW0GQR1XS
PSN1 NF7lVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjPTWM2OD12NT6yOVQ5KM7:TR?= NYntdmd3W0GQR1XS
TE-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV60fopyUUN3ME20OU41QDR{IN88US=> MljBV2FPT0WU
NCI-H1155 M37sZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrGUXc5UUN3ME20OU45QTZ5IN88US=> NF\2dpFUSU6JRWK=
KM12 NWTHNGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHyc495UUN3ME20OU46ODd4IN88US=> M4j5R3NCVkeHUh?=
RO82-W-1 NEfneolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR4Lkm4NlIh|ryP NWHab4J5W0GQR1XS
SW1573 M{XJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LTZhKSzVyPUS3MlM4OzZizszN MXPTRW5ITVJ?
CAKI-1 M1niVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\UTWM2OD12OD6yPFQ2KM7:TR?= M{ixSHNCVkeHUh?=
U-118-MG NGn6XI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXub5B6UUN3ME20PE4{PzB{IN88US=> MYHTRW5ITVJ?
KYSE-520 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHRdJRHUUN3ME20PE41ODF4IN88US=> NVHW[Fd7W0GQR1XS
HT55 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm1XmFKSzVyPUS5MlE1PzRizszN M3nIVnNCVkeHUh?=
ChaGo-K-1 NXm1[Fg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWxb4lKSzVyPUS5MlQ4QTNizszN NIfaS4VUSU6JRWK=
IA-LM NEfSbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD13ND62N|IzKM7:TR?= Ml\qV2FPT0WU
UACC-62 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHH[XF{UUN3ME21OU4yODR4IN88US=> MUTTRW5ITVJ?
MKN7 M4XjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;aSmlEPTB;NU[uNFI5PSEQvF2= M1\zXnNCVkeHUh?=
HPAF-II MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RT2VKSzVyPUW2MlQxPzNizszN NWGxTYZoW0GQR1XS
NTERA-S-cl-D1 NH3VSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTV5Lke3PEDPxE1? MlXoV2FPT0WU
FTC-133 NEH3So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LxTmlEPTB;NUiuNFk3QSEQvF2= NF3mS3lUSU6JRWK=
MHH-ES-1 NYfCRZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\hTWM2OD13OD60PFE1KM7:TR?= MUDTRW5ITVJ?
JVM-2 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTV6Lkm1NFYh|ryP MVjTRW5ITVJ?
TCCSUP MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXewbYI6UUN3ME21PU42Ojd7IN88US=> MmTLV2FPT0WU
COLO-824 NWD4doN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZyLkC3NVkh|ryP NFXZU2lUSU6JRWK=
647-V NGTzZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3YW2FTUUN3ME22NE4yOzR5IN88US=> NVviOWVUW0GQR1XS
HD-MY-Z Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZyLkWyPVQh|ryP M{n5c3NCVkeHUh?=
LS-411N NEjoXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZzLkO5NFMh|ryP NIDUV3dUSU6JRWK=
NCI-H596 NVnhZWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XueGlEPTB;NkKuO|Q6PiEQvF2= MX3TRW5ITVJ?
C-33-A NFq2RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD14ND6wPVU4KM7:TR?= NEXxelFUSU6JRWK=
BHY Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TIOmlEPTB;NkSuNVI1PSEQvF2= MYXTRW5ITVJ?
KGN NV;qW5lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlexTWM2OD14ND61OVE1KM7:TR?= NF3lNnFUSU6JRWK=
NCI-H1092 M1rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXBT3dKSzVyPU[1MlAxQTVizszN M1nQZ3NCVkeHUh?=
MZ1-PC MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTZ3LkW2OFkh|ryP M2\ue3NCVkeHUh?=
LB831-BLC NY\qU4w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfGeGdKSzVyPU[1Mlg1QDFizszN NXrUOmVKW0GQR1XS
SW620 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjWbY9PUUN3ME22Ok4zODN7IN88US=> MXrTRW5ITVJ?
HuO-3N1 NIXRNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP4T|k4UUN3ME22PE4{OjN6IN88US=> NWTUSFVrW0GQR1XS
SK-HEP-1 NHGxRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H3SGlEPTB;NkmuPVQ5PiEQvF2= NInse4FUSU6JRWK=
LCLC-103H M1u0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nH[mlEPTB;N{CuOlcxPSEQvF2= NH;VSWFUSU6JRWK=
KYSE-70 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrDZXI{UUN3ME23NE44QDN3IN88US=> MljiV2FPT0WU
Mewo MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HRc2lEPTB;N{GuOVA2KM7:TR?= MXHTRW5ITVJ?
COLO-668 NXy4TXI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRdHFKSzVyPUexMlg1PTFizszN NYLlcZZbW0GQR1XS
NCI-H522 M2j5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL5TWM2OD15Mj6zOFE{KM7:TR?= NXrHZmpmW0GQR1XS
NCI-H1437 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDsdYxKSzVyPUe0MlQxPDhizszN NF7BUotUSU6JRWK=
U-266 NUf1cIljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILGXXhKSzVyPUe1MlQ2OTZizszN M1vSRnNCVkeHUh?=
MC116 NG\oUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED5b5VKSzVyPUe1MlU4ODhizszN Mk\OV2FPT0WU
PANC-10-05 NUDWW21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrrPJNyUUN3ME23O{41OjR|IN88US=> M2\jZnNCVkeHUh?=
KYSE-180 NXTvd4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTd5LkW0OVQh|ryP MX\TRW5ITVJ?
JAR NXvEVo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXj[GdKSzVyPUe5MlA2PDZizszN Mk\iV2FPT0WU
CAL-62 NFS1TppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3WmhpUUN3ME24NE4xQTVizszN NVHTS4RKW0GQR1XS
A3-KAW M4qyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y5WmlEPTB;OECuNlE2PCEQvF2= NVWxdJEzW0GQR1XS
PANC-08-13 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vUPGlEPTB;OEGuNVc3QCEQvF2= MWTTRW5ITVJ?
HSC-3 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTEbI1KSzVyPUizMlMxPzFizszN MmO5V2FPT0WU
HTC-C3 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTh|LkS3NFIh|ryP NUHucohrW0GQR1XS
KY821 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS5TWM2OD16ND6wPFkzKM7:TR?= NU[yVXFZW0GQR1XS
DoTc2-4510 NX\RNXRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD16ND6yNVg2KM7:TR?= NUDn[lJ4W0GQR1XS
NCI-H1581 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojtTWM2OD16NT60OlQyKM7:TR?= NY\kSpVbW0GQR1XS
KARPAS-299 M1XUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTh4LkG5O|ch|ryP MmP2V2FPT0WU
IST-MEL1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTh4Lki4O|Ih|ryP Mk\oV2FPT0WU
KP-N-YS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjhWHgzUUN3ME24PU46ODJ6IN88US=> NHXCTZdUSU6JRWK=
KYSE-410 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKySXhtUUN3ME25NU41ODR{IN88US=> M376fHNCVkeHUh?=
TE-10 M4nr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjRTWM2OD17MT61OlEyKM7:TR?= NUTvN2k3W0GQR1XS
SK-MEL-1 NWf4XFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQUI44UUN3ME25Nk46OTB4IN88US=> MlnaV2FPT0WU
COLO-792 NHXwPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCzTWM2OD17NT6yOVY1KM7:TR?= NVLYdYhEW0GQR1XS
SCH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTWeoRKUUN3ME25Ok4{QDd5IN88US=> MWnTRW5ITVJ?
NCI-H1792 NFzITYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TlTmlEPTB;OU[uPFk6OiEQvF2= NVnybpp{W0GQR1XS
NCI-H2029 M1v3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQXmRkUUN3ME25Ok46PTZ4IN88US=> NFjVbphUSU6JRWK=
SW684 NXy4N3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LPUGlEPTB;OUiuOlY2PCEQvF2= MV7TRW5ITVJ?
NCI-H209 NF7YdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFyMD6xNlEh|ryP M3rOSXNCVkeHUh?=
HLE NEjKeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHYZWtKSzVyPUGwOU4zQDJizszN M1rTbHNCVkeHUh?=
GOTO NIrLbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyNz63O|ch|ryP MnfnV2FPT0WU
NCI-H1793 NGXrXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nmOGlEPTB;MUC5MlI5KM7:TR?= MmTiV2FPT0WU
D-392MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFzNz6zPVgh|ryP Mmn5V2FPT0WU
SW1990 M1HnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfhTWM2OD1zMkCuPVUyKM7:TR?= MULTRW5ITVJ?
ML-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj2OZZMUUN3ME2xNlEvPjd4IN88US=> NHLSN21USU6JRWK=
NCI-H2452 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ZPFVKSzVyPUGyNk4zOSEQvF2= MYnTRW5ITVJ?
SK-MEL-30 NETOZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ztRmlEPTB;MUKzMlI1PCEQvF2= NYDxO5NuW0GQR1XS
SN12C M{TJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TX[2lEPTB;MUK0MlE4PiEQvF2= M3K5ZnNCVkeHUh?=
NCI-H1770 M17UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv6XIJKSzVyPUGyOU42OTRizszN MXvTRW5ITVJ?
SF268 NFO3bZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnizTWM2OD1zMk[uNVU5KM7:TR?= NFfOZYxUSU6JRWK=
BALL-1 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF{Nj6yN{DPxE1? M{\BfnNCVkeHUh?=
COLO-679 NUfMbnA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PuO2lEPTB;MUK2Mlc2OyEQvF2= NH7HTVFUSU6JRWK=
A2780 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu1TWM2OD1zMkiuPVg5KM7:TR?= NXvCUnVMW0GQR1XS
NCI-H1651 M2PuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD1zM{GuNlQ{KM7:TR?= NIjBOWRUSU6JRWK=
NCI-H2087 M{C2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDoOIJKSzVyPUGzNU41QDNizszN Mm\VV2FPT0WU
U-87-MG Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHBd4s3UUN3ME2xN|MvPjB2IN88US=> Mm\5V2FPT0WU
LB2518-MEL NIX3[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX24NHpYUUN3ME2xN|UvQTl|IN88US=> M2TRVHNCVkeHUh?=
HCT-116 NWDLbpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnaS29oUUN3ME2xN|cvOjF5IN88US=> NYGwbXlrW0GQR1XS
Ca9-22 NIW1bHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KxV2lEPTB;MUO5Mlg{OyEQvF2= NW\XXW1EW0GQR1XS
COR-L88 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\UUHJuUUN3ME2xOFIvOTRizszN M4rkNXNCVkeHUh?=
CP50-MEL-B NXTUZmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2ND61NFEh|ryP Ml7DV2FPT0WU
OVCAR-8 NWTldFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XnZmlEPTB;MUS1MlY{PiEQvF2= NVTxNms1W0GQR1XS
SK-MEL-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TGcWlEPTB;MUS3Mlg4QCEQvF2= MWPTRW5ITVJ?
GT3TKB M1;mRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n4S2lEPTB;MUS5MlkzQCEQvF2= NEnYTWNUSU6JRWK=
KYSE-450 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0ZWNKSzVyPUG1NU42OzlizszN MUjTRW5ITVJ?
CAPAN-1 M3T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF3Mz6wOlQh|ryP NIf1fGxUSU6JRWK=
BEN NVrlNlZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF3Mz65Nlgh|ryP Ml3xV2FPT0WU
NCI-H1304 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PROmlEPTB;MUW0MlY6PCEQvF2= MWPTRW5ITVJ?
KU812 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF3OD62O|Qh|ryP Mk\pV2FPT0WU
Capan-2 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz5TWM2OD1zNkCuOVU{KM7:TR?= MYHTRW5ITVJ?
A673 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF4MT63NFUh|ryP NEjncHBUSU6JRWK=
SAS NEDUNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3cIFKSzVyPUG2Nk43PzhizszN M3fTSHNCVkeHUh?=
NY M4PKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rZdGlEPTB;MU[1MlMyPCEQvF2= MX3TRW5ITVJ?
HCE-4 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG4WmRKSzVyPUG2Ok45PDVizszN NHO5cYhUSU6JRWK=
MDA-MB-231 NUnSXVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF5Nz61NFMh|ryP MVPTRW5ITVJ?
no-10 M17nbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1frXmlEPTB;MUe4MlE{PCEQvF2= MmTuV2FPT0WU
MZ7-mel Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG2dYxtUUN3ME2xO|gvPDZ5IN88US=> MYrTRW5ITVJ?
NCI-H82 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHmcoJKSzVyPUG4NE4yPjVizszN M332SXNCVkeHUh?=
CAL-72 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\hTWM2OD1zOEWuNFU1KM7:TR?= M{\ye3NCVkeHUh?=
NCI-SNU-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnGPIpPUUN3ME2xPFYvQDRizszN MXrTRW5ITVJ?
OVCAR-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvPSIxKSzVyPUG4PE4{OzNizszN MYXTRW5ITVJ?
SCC-9 NHfEcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfUenhKSzVyPUG5NUDPxE1? NFnv[lRUSU6JRWK=
KYSE-150 NFnjXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpW2lEPTB;MUmxMlg5QCEQvF2= NIHF[GFUSU6JRWK=
HT-29 NFz6dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r6S2lEPTB;MkCxMlIyOiEQvF2= MY\TRW5ITVJ?
COLO-678 M2KyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO5TWM2OD1{MEGuOFUh|ryP MlLZV2FPT0WU
NCI-H650 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJyMj6xNFMh|ryP M1ixfnNCVkeHUh?=
HuCCT1 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O2VGlEPTB;MkC0MlIxQCEQvF2= NV7mNIRRW0GQR1XS
SW1116 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJyNz6wO|ch|ryP NWPOSYNbW0GQR1XS
DBTRG-05MG NEfL[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjIVWpKSzVyPUKwO{46ODlizszN NIjJNo9USU6JRWK=
SW982 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJyNz65OFgh|ryP Ml;tV2FPT0WU
RCM-1 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWraNXdzUUN3ME2yNVQvPzZ{IN88US=> NIfmOGVUSU6JRWK=
COLO-320-HSR MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJzNj6xNlUh|ryP NGG3co5USU6JRWK=
KNS-42 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnFelFKSzVyPUKxOk42PzRizszN NVP3SXR6W0GQR1XS
C2BBe1 NVKxR4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDBT|R3UUN3ME2yN|EvQTB3IN88US=> NXvhc44{W0GQR1XS
CCRF-CEM NGHxeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ2Mz63PVUh|ryP Mmf2V2FPT0WU
SH-4 M4q1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrmPINKSzVyPUK0Ok4xQSEQvF2= M33SWXNCVkeHUh?=
LS-1034 NY\QRZdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PK[mlEPTB;MkS2MlI3PiEQvF2= MW\TRW5ITVJ?
NCI-H2347 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[1b29KSzVyPUK0O{44OTNizszN NWD3[XM4W0GQR1XS
RPMI-8866 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ2OT6yO{DPxE1? MX3TRW5ITVJ?
GAK M2\YXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;BOmJCUUN3ME2yOVMvODB{IN88US=> NWTtenloW0GQR1XS
NB6 NYLyeGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv2TXBiUUN3ME2yO|AvOSEQvF2= Moi4V2FPT0WU
COLO-680N M3nHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDwOXdKSzVyPUK3Nk42OjdizszN M1q2cnNCVkeHUh?=
RERF-LC-MS NWiwbIczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ5Nj6wNFch|ryP MlvpV2FPT0WU
TGBC11TKB NXPBXol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnDbnU2UUN3ME2yO|gvOTd6IN88US=> MmDIV2FPT0WU
C8166 M{PWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\uXlVKSzVyPUK3PE42ODZizszN MYjTRW5ITVJ?
HDLM-2 NU\DZ5RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELkR4dKSzVyPUK5OE41ODlizszN M2XxVXNCVkeHUh?=
IGR-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4TWpIUUN3ME2yPVUvPjV7IN88US=> NFPuPJdUSU6JRWK=
FADU NEXyeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjvTWM2OD1{OUeuOVEh|ryP M3y4OHNCVkeHUh?=
L-428 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[1TWM2OD1{OUeuOlE3KM7:TR?= MY\TRW5ITVJ?
LU-65 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLIXpdKSzVyPUOwOE4{OiEQvF2= M4La[XNCVkeHUh?=
HEL Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmezTWM2OD1|MEmuPVg{KM7:TR?= MVjTRW5ITVJ?
NCI-H810 NF7jfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjFPFFKSzVyPUOxNE42PyEQvF2= NXHzRYljW0GQR1XS
C3A MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvSbYRKSzVyPUOxNU45ODJizszN NEP3N4RUSU6JRWK=
NCI-H630 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjJT49kUUN3ME2zN|IvOjl2IN88US=> NYG4ZWF2W0GQR1XS
KP-N-YN NGrLeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN2MT6xNlMh|ryP MVvTRW5ITVJ?
MOLT-13 M3r3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTRTWM2OD1|NEKuN|I3KM7:TR?= NULPOHRoW0GQR1XS
NCI-H1993 NEHMU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXlTWM2OD1|NEKuN|Y2KM7:TR?= MkLwV2FPT0WU
BE-13 M2rrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2TWM2OD1|NESuNVY4KM7:TR?= M{XFSXNCVkeHUh?=
IST-SL1 NFHqXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGzVWFpUUN3ME2zOFcvPDBzIN88US=> MV;TRW5ITVJ?
TE-9 NYHWVnA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTJUmdLUUN3ME2zOlMvPTh7IN88US=> M2\2UHNCVkeHUh?=
LU-135 NHnwdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLnTWM2OD1|NkeuNFM2KM7:TR?= NUDKcJU3W0GQR1XS
T84 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN5ND63NVIh|ryP MnXhV2FPT0WU
K-562 NVjpSYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XTZ2lEPTB;M{izMlM3KM7:TR?= MUfTRW5ITVJ?
SBC-5 M1LKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[5R2NKSzVyPUO4Ok46QDVizszN NYnBdZBlW0GQR1XS
NB17 M1ntTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfTTWM2OD1|OUKuOVk3KM7:TR?= NIe3emFUSU6JRWK=
NCI-H2052 NVTsRpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vMfWlEPTB;M{m4MlQ4OiEQvF2= M{XnZ3NCVkeHUh?=
HCC38 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml31TWM2OD12MEGuOVk{KM7:TR?= MXPTRW5ITVJ?
NCI-H69 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR2MT6wPFMh|ryP MlriV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

プロトコル(参考用のみ)

キナーゼアッセイ:[4]
+ 展開

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
細胞アッセイ: [2]
+ 展開
  • 細胞株: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • 濃度: 0, 0.3, 1 and 3 μM
  • 反応時間: 72 or 96 hours
  • 実験の流れ: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (参考用のみ)
動物実験:[2]
+ 展開
  • 動物モデル: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • 製剤: Formulated in 30% Captisol
  • 投薬量: 120 mg/kg
  • 投与方法: Orally administered
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 15% Captisol 17 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 480.39
化学式

C25H21N5O.2HCl

CAS No. 1032350-13-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 問題2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt信号経路図

Akt Inhibitors with Unique Features

相関Akt製品

Tags: MK-2206 2HClを買う | MK-2206 2HCl ic50 | MK-2206 2HCl供給者 | MK-2206 2HClを購入する | MK-2206 2HCl費用 | MK-2206 2HCl生産者 | オーダーMK-2206 2HCl | MK-2206 2HCl化学構造 | MK-2206 2HCl分子量 | MK-2206 2HCl代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID